Bookmark
Forward
KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
Ugo De Giorgi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Mar 20
Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Ugo De Giorgi.
KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007 Mar 20;25(9):1146-7; author reply 1147-8
Mesh Tags
Antineoplastic Agents
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Exons
Gastrointestinal Stromal Tumors
Humans
Mutation
Piperazines
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-kit
Pyrimidines
Randomized Controlled Trials as Topic
Research Design
Treatment Failure
Substances
Antineoplastic Agents
Piperazines
Protein Kinase Inhibitors
Pyrimidines
imatinib
Proto-Oncogene Proteins c-kit
PMID: 17369583
View Full Text